Disease Detail

ID DOID:3070
Name malignant glioma
Definition A cell type cancer that has material basis in glial cells and is located in brain or located in spine.
Source DiseaseOntology.org
Alt Ids DOID:2627
Path disease disease of cellular proliferation cancer cell type cancer malignant glioma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Mithramycin malignant glioma not applicable detail...
IDH1 R132C AGI-5198 malignant glioma sensitive detail...
IDH1 R132H AGI-5198 malignant glioma sensitive detail...
Unknown unknown MRX34 malignant glioma not applicable detail...
Unknown unknown Sunitinib malignant glioma not applicable detail...
FGFR3-TACC3 PD173074 malignant glioma sensitive detail...
FGFR1-TACC1 PD173074 malignant glioma sensitive detail...
FGFR3-TACC3 AZD4547 malignant glioma sensitive detail...
FGFR1-TACC1 AZD4547 malignant glioma sensitive detail...
FGFR1-TACC1 BGJ398 malignant glioma sensitive detail...
FGFR3-TACC3 BGJ398 malignant glioma sensitive detail...
Unknown unknown PQ401 malignant glioma not applicable detail...
FGFR3-TACC3 Erdafitinib malignant glioma sensitive detail...
HRAS G12V SF1126 malignant glioma sensitive detail...
IDH1 mutant N/A malignant glioma not applicable detail...
ATRX loss IDH1 mut Gemcitabine + Radiotherapy malignant glioma predicted - sensitive detail...
Unknown unknown GDC-0084 malignant glioma not applicable detail...
Unknown unknown ADDA 5 malignant glioma not applicable detail...
BRAF V600E Everolimus + Selumetinib malignant glioma predicted - sensitive detail...
BRAF V600E Selumetinib + PLX4720 malignant glioma predicted - sensitive detail...
BRAF V600E Everolimus + PLX4720 malignant glioma predicted - sensitive detail...
BRAF wild-type Everolimus + Selumetinib malignant glioma predicted - sensitive detail...
IDH1 mutant Ivosidenib malignant glioma sensitive detail...
Unknown unknown Everolimus malignant glioma not applicable detail...
Unknown unknown Bevacizumab + Marizomib malignant glioma not applicable detail...
Unknown unknown Toca 511 + Toca FC malignant glioma not applicable detail...
IDH1 R132H BPTES malignant glioma sensitive detail...
IDH1 R132H Talazoparib malignant glioma sensitive detail...
IDH1 R132C Talazoparib malignant glioma sensitive detail...
MET act mut Merestinib malignant glioma sensitive detail...
Unknown unknown AdV-tk + Valacyclovir malignant glioma not applicable detail...
Unknown unknown PV1019 + Radiotherapy malignant glioma not applicable detail...
IDH2 R140Q AG-881 malignant glioma predicted - sensitive detail...
IDH1 R132H AG-881 malignant glioma predicted - sensitive detail...
Unknown unknown Palomid 529 malignant glioma not applicable detail...
IDH2 mutant N/A malignant glioma not applicable detail...
IDH1 R132H N/A malignant glioma not applicable detail...
IDH1 wild-type N/A malignant glioma not applicable detail...
IDH2 wild-type N/A malignant glioma not applicable detail...
ATRX mutant N/A malignant glioma not applicable detail...
Unknown unknown DNX-2401 malignant glioma not applicable detail...
Unknown unknown NEO212 malignant glioma not applicable detail...
Unknown unknown Bevacizumab + MEDI3617 malignant glioma not applicable detail...
BRAF V600E Vemurafenib malignant glioma predicted - sensitive detail...
Unknown unknown NEO214 malignant glioma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00876993 Phase I Temozolomide + Irinotecan + Bevacizumab Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Completed
NCT00879437 Phase II Bevacizumab Valproic acid Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas Active, not recruiting
NCT01052363 Phase I Bevacizumab + Fosbretabulin OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas Withdrawn
NCT01089101 Phase Ib/II Selumetinib Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting
NCT01107522 Phase I CTO + Temozolomide Carboxyamidotriazole Orotate Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Active, not recruiting
NCT01130077 Phase I poly ICLC A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas Recruiting
NCT01156584 Phase I Toca 511 + Toca FC A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma Completed
NCT01188096 Phase II poly ICLC A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas Active, not recruiting
NCT01266031 Phase Ib/II Bevacizumab + Vorinostat Bevacizumab Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma Completed
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed
NCT01392209 Phase I Bevacizumab Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma Active, not recruiting
NCT01434602 Phase Ib/II Everolimus + Sorafenib Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas Recruiting
NCT01435395 Phase I Bevacizumab + Bortezomib + Temozolomide Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme Completed
NCT01478178 Phase Ib/II VAL-083 Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor Completed
NCT01478321 Phase II Bevacizumab + Temozolomide Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Active, not recruiting
NCT01547546 Phase I GDC-0084 A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma Completed
NCT01644773 Phase I Crizotinib + Dasatinib Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Completed
NCT01648348 Phase Ib/II Carotuximab Bevacizumab Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Completed
NCT01661400 Phase I Cyclophosphamide Thalidomide Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors Recruiting
NCT01743950 Phase II Bevacizumab A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab Recruiting
NCT01748149 Phase I Vemurafenib Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas Active, not recruiting
NCT01817751 Phase II Valproic acid Sorafenib Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma Recruiting
NCT01903330 Phase II Bevacizumab Cyclophosphamide Sargramostim ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme Recruiting
NCT01925573 Phase I Bevacizumab NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) Recruiting
NCT01954030 Phase Ib/II Bevacizumab Carboxyamidotriazole Orotate Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure Terminated
NCT01977677 Phase Ib/II Temozolomide Plerixafor Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
NCT01985256 Phase I Toca 511 Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor Completed
NCT01989052 Phase Ib/II Lomustine Carboxyamidotriazole Orotate Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Terminated
NCT02017717 Phase III Nivolumab Bevacizumab Nivolumab + Ipilimumab A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) Active, not recruiting
NCT02023905 Phase II Temozolomide Everolimus Everolimus With and Without Temozolomide in Adult Low Grade Glioma Active, not recruiting
NCT02026271 Phase I Ad-RTS-IL-12 plus AL A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Active, not recruiting
NCT02034110 Phase II Trametinib + Dabrafenib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting
NCT02052648 Phase Ib/II Temozolomide indoximod Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Active, not recruiting
NCT02101905 Phase I Lapatinib Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Recruiting
NCT02186509 Phase I Alisertib Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Active, not recruiting
NCT02193347 Phase I PEPIDH1M vaccine RESIST: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine Active, not recruiting
NCT02238496 Phase II Perifosine + Temsirolimus Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Unknown status
NCT02273739 Phase Ib/II Enasidenib Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed
NCT02311582 Phase Ib/II Pembrolizumab MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas Recruiting
NCT02313272 Phase I Bevacizumab + Pembrolizumab Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas Active, not recruiting
NCT02323880 Phase I Selinexor Study of Selinexor in Pediatric Solid Tumors Recruiting
NCT02330562 Phase I Bevacizumab + Marizomib Study of Marizomib With Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Recruiting
NCT02332889 Phase Ib/II Decitabine poly ICLC Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs Terminated
NCT02337491 Phase II Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab +/- Bevacizumab for Recurrent GBM Active, not recruiting
NCT02337686 Phase II Pembrolizumab Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma Active, not recruiting
NCT02343718 Phase I Temsirolimus + Vinblastine Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours Completed
NCT02345824 Phase I Ribociclib Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma Active, not recruiting
NCT02358187 Phase II poly ICLC A Vaccine Trial for Low Grade Gliomas Recruiting
NCT02359565 Phase I Pembrolizumab Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas Recruiting
NCT02366728 Phase II pp65 Dendritic Cell Vaccine + Temozolomide C Migration Study for Newly-Diagnosed GBM (ELEVATE) Active, not recruiting
NCT02372006 Phase I Afatinib Phase I Trial of Afatinib in Pediatric Tumours Recruiting
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Active, not recruiting
NCT02423525 Phase I Afatinib Safety Study of Afatinib for Brain Cancer Recruiting
NCT02481154 Phase I AG-881 Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation Active, not recruiting
NCT02502708 Phase I indoximod Temozolomide Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors Recruiting
NCT02507583 Phase I IGF-1R/AS ODN Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma Active, not recruiting
NCT02529072 Phase I Nivolumab Nivolumab With DC Vaccines for Recurrent Brain Tumors Active, not recruiting
NCT02540161 Phase II SYM004 Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma Active, not recruiting
NCT02607124 Phase Ib/II Ribociclib Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Active, not recruiting
NCT02639546 Phase I Cobimetinib iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors Recruiting
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting
NCT02655601 Phase Ib/II BMX-001 + Temozolomide Temozolomide Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Recruiting
NCT02658279 Phase I Pembrolizumab Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype Recruiting
NCT02669173 Phase I Bevacizumab + Capecitabine Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma Recruiting
NCT02684058 Phase II Trametinib + Dabrafenib Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG Recruiting
NCT02743078 Phase II Bevacizumab Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Active, not recruiting
NCT02768389 Phase I Bevacizumab Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Completed
NCT02794883 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Recruiting
NCT02829931 Phase I Nivolumab Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas Recruiting
NCT02833701 Phase I Bevacizumab Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma Active, not recruiting
NCT02840409 Phase II Vinblastine Bevacizumab + Vinblastine Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) Recruiting
NCT02852655 Phase 0 Pembrolizumab A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Active, not recruiting
NCT02859857 Phase I BXQ-350 Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors Recruiting
NCT02871843 Phase I RRx-001 + Temozolomide Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1) Active, not recruiting
NCT02885324 Phase II Cabozantinib Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children Recruiting
NCT02924038 Phase I IMA950 + poly ICLC Varlilumab A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) Recruiting
NCT02933736 Phase 0 Ribociclib Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients Recruiting
NCT02968940 Phase III Avelumab Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Active, not recruiting
NCT02977689 Phase II IDH305 Trial of IDH305 in IDH1 Mutant Grade II or III Glioma Withdrawn
NCT02986178 Phase II Lomustine + PVSRIPO PVSRIPO PVSRIPO With/Without Lomustine Recruiting
NCT03095248 Phase II Selumetinib Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting
NCT03130959 Phase II Nivolumab + Ipilimumab Nivolumab An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) Recruiting
NCT03134131 Expanded access ONC201 Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma Available
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting
NCT03174197 Phase Ib/II Atezolizumab + Temozolomide Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM) Recruiting
NCT03212274 Phase II Olaparib Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Recruiting
NCT03220646 Phase II Abemaciclib The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors. Recruiting
NCT03245151 Phase Ib/II Everolimus + Lenvatinib Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors Recruiting
NCT03283631 Phase I EGFR-vIII CAR-T Cells Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM Suspended
NCT03295396 Phase II ONC201 ONC201 in Adults With Recurrent High-grade Glioma Recruiting
NCT03352427 Phase II Dasatinib + Everolimus Everolimus Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR/FGFR Alterations Recruiting
NCT03355794 Phase I Ribociclib + Everolimus A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Recruiting
NCT03387020 Phase I Ribociclib Ribociclib + Everolimus Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Recruiting
NCT03389230 Phase I HER2 CAR-T cells Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Recruiting
NCT03416530 Phase I ONC201 ONC201 in Pediatric H3 K27M Gliomas Recruiting
NCT03426891 Phase I Pembrolizumab + Temozolomide + Vorinostat Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Recruiting
NCT03452930 Phase I Tinostamustine EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM) Recruiting
NCT03463265 Phase II Lomustine + Nab-Rapamycin Nab-Rapamycin Nab-Rapamycin + Temozolomide Bevacizumab + Nab-Rapamycin ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma Recruiting
NCT03514069 Phase I Ruxolitinib Ruxolitinib + Temozolomide Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma Recruiting
NCT03532295 Phase Ib/II Avelumab + Bevacizumab + Epacadostat Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas Not yet recruiting
NCT03557359 Phase II Nivolumab Nivolumab for Recurrent or Progressive IDH Mutant Gliomas Recruiting
NCT03581292 Phase II Veliparib + Temozolomide Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations Recruiting
NCT03598244 Phase I Savolitinib Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors Suspended
NCT03605550 Phase I PTC596 A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Recruiting
NCT03632317 Phase II Panobinostat + Everolimus A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Recruiting
NCT03690869 Phase Ib/II Cemiplimab REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Recruiting
NCT03696355 Phase I GDC-0084 Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas Recruiting
NCT03718767 Phase II Nivolumab Nivolumab in People With IDH-Mutant Gliomas With and Without Hypermutator Phenotype Not yet recruiting
NCT03746080 Phase II Plerixafor + Temozolomide Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma Recruiting
NCT03749187 Phase I Pamiparib + Temozolomide BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017) Not yet recruiting
NCT03763396 Phase I Posaconazole Ketoconazole Azoles Targeting Recurrent High Grade Gliomas Not yet recruiting
NCT03834740 Phase I Ribociclib + Everolimus Ph0/2 Ribociclib & Everolimus Recruiting